Devices for the treatment of arterial hypertension

[1] Bunker J, Chang CL, Chapman N, Poulter N, Thom S, Thornton-Jones L, Sever P. True resistant hypertension following observed drug ingestion: A systematic evaluation. J Clin Hypertens. 2017; 19: 250–255. BunkerJ ChangCL ChapmanN PoulterN ThomS Thornton-JonesL SeverP True resistant hypertension following observed drug ingestion: A systematic evaluation J Clin Hypertens 2017 19 250 255 Search in Google Scholar

[2] Vega J, Bisogano JD. The prevalence, incidence, prognosis, and associated conditions of resistant hypertension. Semin Nephrol. 2014; 34: 247–256. VegaJ BisoganoJD The prevalence, incidence, prognosis, and associated conditions of resistant hypertension Semin Nephrol 2014 34 247 256 Search in Google Scholar

[3] Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, Samani NJ, Gupta P, Madira W, Stanley A, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014; 100: 855–861. TomaszewskiM WhiteC PatelP MascaN DamaniR HepworthJ SamaniNJ GuptaP MadiraW StanleyA High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis Heart 2014 100 855 861 Search in Google Scholar

[4] Peacock E, Krousel-Wood M. Adherence to antihypertensive therapy. Med Clin North Am. 2017; 101: 229–245. PeacockE Krousel-WoodM Adherence to antihypertensive therapy Med Clin North Am 2017 101 229 245 Search in Google Scholar

[5] Bergo KK, Larstorp AC, Hoffmann P, Hjørnholm U, Cataliotti A, Høieggen A, Rostrup M, Fadl Elmula FEM. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood Press 2021; 30: 31–40. BergoKK LarstorpAC HoffmannP HjørnholmU CataliottiA HøieggenA RostrupM Fadl ElmulaFEM Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension Blood Press 2021 30 31 40 Search in Google Scholar

[6] Carey RM, Calhoun JL, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, et al. Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Association. Hypertension. 2018; 72: e53–e90. CareyRM CalhounJL BakrisGL BrookRD DaughertySL Dennison-HimmelfarbCR EganBM FlackJM GiddingSS JuddE Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Association Hypertension 2018 72 e53 e90 Search in Google Scholar

[7] Esler M. The sympathetic nervous system in hypertension: back to the future? Curr Hypertens Rep. 2015; 17: 11. doi: 10.1007/s11906-014-0519-8. EslerM The sympathetic nervous system in hypertension: back to the future? Curr Hypertens Rep 2015 17 11 10.1007/s11906-014-0519-8 Open DOISearch in Google Scholar

[8] Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res. 2015; 116: 976–990. GrassiG MarkA EslerM The sympathetic nervous system alterations in human hypertension Circ Res 2015 116 976 990 Search in Google Scholar

[9] Schlainch MP, Sobotka PA, Kum H, Lambert E, Esler M. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009; 361: 932–934. SchlainchMP SobotkaPA KumH LambertE EslerM Renal sympathetic-nerve ablation for uncontrolled hypertension N Engl J Med 2009 361 932 934 Search in Google Scholar

[10] Lohmeier TE, Hall JE. Device-based neuromodulation for resistant hypertension therapy: too early for prime time? Circ Res. 2019; 14: 1071–1093. LohmeierTE HallJE Device-based neuromodulation for resistant hypertension therapy: too early for prime time? Circ Res 2019 14 1071 1093 Search in Google Scholar

[11] Kalarus Z, Merkey B, Neuzil O, Grabowski M, Mitkowski P, Marinskis G, Erglis A, Kaźmierczak JTA, Pluta S, Gellér L, et al. Pacemaker-based cardiac neuromodulation therapy in patients with hypertension. A pilot study. Am Heart Association. 2021; 10, Nr 16: e020492. doi: 10.1161/JAHA.120.020492. KalarusZ MerkeyB NeuzilO GrabowskiM MitkowskiP MarinskisG ErglisA KaźmierczakJTA PlutaS GellérL Pacemaker-based cardiac neuromodulation therapy in patients with hypertension. A pilot study Am Heart Association 2021 10 16 e020492 10.1161/JAHA.120.020492 Open DOISearch in Google Scholar

[12] Esler MD. Krum H. Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial. Lancet. 2010; 376: 1903–1909. EslerMD KrumH SobotkaPA SchlaichMP SchmiederRE BöhmM Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial Lancet 2010 376 1903 1909 Search in Google Scholar

[13] Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multi-centre safety and proof-of-principle cohort study. Lancet. 2009; 373: 1275–1281. KrumH SchlaichM WhitbournR SobotkaPA SadowskiJ BartusK KapelakB WaltonA SievertH ThambarS Catheter-based renal sympathetic denervation for resistant hypertension: a multi-centre safety and proof-of-principle cohort study Lancet 2009 373 1275 1281 Search in Google Scholar

[14] Bhatt D, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, et al. Controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014; 370: 1393–1401. BhattD KandzariDE O’NeillWW D’AgostinoR FlackJM KatzenBT LeonMB LiuM MauriL NegoitaM Controlled trial of renal denervation for resistant hypertension N Engl J Med 2014 370 1393 1401 Search in Google Scholar

[15] Mahfoud F, Schlaich MP, Lobo MD. Device therapy of hypertension. Circulation Research. 2021; 128: 1080–1099. MahfoudF SchlaichMP LoboMD Device therapy of hypertension Circulation Research 2021 128 1080 1099 Search in Google Scholar

[16] Bohm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, Ruilope L, Schlaich MP, Schmieder RE, Whitbourn R, et al. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension. 2015; 65: 766–774. BohmM MahfoudF UkenaC HoppeUC NarkiewiczK NegoitaM RuilopeL SchlaichMP SchmiederRE WhitbournR First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension Hypertension 2015 65 766 774 Search in Google Scholar

[17] Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, Mounier-Véhier C, Courand PY, Lantelme P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015; 385: 1957–1965. AziziM SapovalM GosseP MongeM BobrieG DelsartP MidullaM Mounier-VéhierC CourandPY LantelmeP Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial Lancet 2015 385 1957 1965 Search in Google Scholar

[18] Mahfoud F, Böhm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L, Schlaich M, Williams B, Fahy M, Mancia G. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J. 2019; 40: 3474–3482. MahfoudF BöhmM SchmiederR NarkiewiczK EwenS RuilopeL SchlaichM WilliamsB FahyM ManciaG Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry Eur Heart J 2019 40 3474 3482 Search in Google Scholar

[19] Booth LC, Nishi EE, Yao ST, Ramchandra R, Lambert GW, Schlaich MP, May CN. Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep. Hypertension. 2015; 65: 393–400. BoothLC NishiEE YaoST RamchandraR LambertGW SchlaichMP MayCN Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep Hypertension 2015 65 393 400 Search in Google Scholar

[20] Mompeo B, Marnillo E, Garcia-Touchrd A, Larkin T, Sanudo J. The gross anatomy of the renal sympathetic nerve revisited. Clin Anat. 2016; 29: 660–664. MompeoB MarnilloE Garcia-TouchrdA LarkinT SanudoJ The gross anatomy of the renal sympathetic nerve revisited Clin Anat 2016 29 660 664 Search in Google Scholar

[21] Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler DR, Kolodgie FD, Virmani R, Joner M. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol. 2014; 64: 635–643. SakakuraK LadichE ChengQ OtsukaF YahagiK FowlerDR KolodgieFD VirmaniR JonerM Anatomic assessment of sympathetic peri-arterial renal nerves in man J Am Coll Cardiol 2014 64 635 643 Search in Google Scholar

[22] Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, Ewen S, Tsioufis K, Tousoulis D, Sharp ASP, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017; 390: 2160–2170. TownsendRR MahfoudF KandzariDE KarioK PocockS WeberMA EwenS TsioufisK TousoulisD SharpASP Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial Lancet 2017 390 2160 2170 Search in Google Scholar

[23] Kandzari DE, Bohm M, Mahfoud F, Weber A, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S, et al. Effect of renal denervation on blood pressure of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-concept randomized trial. Lancet. 2018; 391: 2346–2355. KandzariDE BohmM MahfoudF WeberA PocockS TsioufisK TousoulisD ChoiJW EastC BrarS Effect of renal denervation on blood pressure of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-concept randomized trial Lancet 2018 391 2346 2355 Search in Google Scholar

[24] Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, Basile J, Kirtane AJ, Wang Y, Lobo MD, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018; 391: 2335–2345. AziziM SchmiederRE MahfoudF WeberMA DaemenJ DaviesJ BasileJ KirtaneAJ WangY LoboMD Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial Lancet 2018 391 2335 2345 Search in Google Scholar

[25] Azizi M, Daemen J, Lobo MD, Mahfoud F, Sharp ASP, Schmieder RE, Wang Y, Saxena M, Lurz P, Sayer J, et al. 12 months result from the un-blinded phase of the RADIANCE-HTN SOLO Trial of ultrasound renal denervation. JACC-Cardiovasc Interv. 2020; 13: 2922–2933. AziziM DaemenJ LoboMD MahfoudF SharpASP SchmiederRE WangY SaxenaM LurzP SayerJ 12 months result from the un-blinded phase of the RADIANCE-HTN SOLO Trial of ultrasound renal denervation JACC-Cardiovasc Interv 2020 13 2922 2933 Search in Google Scholar

[26] Chermin G, Szwarcfiter I, Scheinert A, Blessing E, Diehm N, Dens J, Walton A, Verheye S, Shetty S, Jonas M. First-in man experience with a novel catheter-based renal denervation system of ultrasonic ablation in patients with resistant hypertension. J Vasc Interv Radiol. 2018; 299: 1158–1166. CherminG SzwarcfiterI ScheinertA BlessingE DiehmN DensJ WaltonA VerheyeS ShettyS JonasM First-in man experience with a novel catheter-based renal denervation system of ultrasonic ablation in patients with resistant hypertension J Vasc Interv Radiol 2018 299 1158 1166 Search in Google Scholar

[27] Schmieder RE, Ott C, Toennes SW, Bramlage P, Gertner M, Dawood O, Baumgart P, O’Brien B, Dasgupta I, Nickenig G, et al. Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV. J Hypertens. 2018 Mar; 36: 680–689. doi: 10.1097/HJH.0000000000001584. PMID: 29035942 SchmiederRE OttC ToennesSW BramlageP GertnerM DawoodO BaumgartP O’BrienB DasguptaI NickenigG Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV J Hypertens 2018 Mar 36 680 689 10.1097/HJH.0000000000001584 29035942 Open DOISearch in Google Scholar

[28] Mahfoud F, Renkin J, Sievert H, Bertog S, Ewen S, Böhm M, Lengelé JP, Wojakowski W, Schmieder R, van der Giet M, et al. Alcohol-mediated renal denervation using the peregrine system infusion catheter for treatment of hypertension. JACC. Cardiovasc Inter. 2020; 13: 471–484. MahfoudF RenkinJ SievertH BertogS EwenS BöhmM LengeléJP WojakowskiW SchmiederR van der GietM Alcohol-mediated renal denervation using the peregrine system infusion catheter for treatment of hypertension JACC. Cardiovasc Inter 2020 13 471 484 Search in Google Scholar

[29] Haribabu S, Sharif F, Zafar H. Recent trends in renal denervation devices for resistant hypertension treatment. Irish J Med. Science. 2021; 190: 971–997. HaribabuS SharifF ZafarH Recent trends in renal denervation devices for resistant hypertension treatment Irish J Med. Science 2021 190 971 997 Search in Google Scholar

[30] Cheng X, Zhang D, Luo S, Qin S. Effect of catheter-based renal denervation on uncontrolled hypertension: A systematic review and meta-analysis. Mayo Clin Proc. 2019; 94: 1695–1706. ChengX ZhangD LuoS QinS Effect of catheter-based renal denervation on uncontrolled hypertension: A systematic review and meta-analysis Mayo Clin Proc 2019 94 1695 1706 Search in Google Scholar

[31] Maqsood MH, Rubab K, Anwar F, Khan AMT, Maqsood MA, Farooq M, Tabaza L, Rangaswami J, Virk HUH. A systematic review of randomized controlled trials comparing renal sympathetic denervation versus sham procedure for the management of uncontrolled hypertension. J Cardiovasc Pharmacol. 2021; 77: 153–158. MaqsoodMH RubabK AnwarF KhanAMT MaqsoodMA FarooqM TabazaL RangaswamiJ VirkHUH A systematic review of randomized controlled trials comparing renal sympathetic denervation versus sham procedure for the management of uncontrolled hypertension J Cardiovasc Pharmacol 2021 77 153 158 Search in Google Scholar

[32] Ogoyama Y, Tada K, Abe M, Nanto S, Shibata H, Mukoyama M, Kai H, Arima H, Kario K. Effects of renal denervation on blood pressures in patients with hypertension: a systematic review and meta-analysis of randomized sham-controlled trials. Hypertens Res. 2022; 45: 210–220. OgoyamaY TadaK AbeM NantoS ShibataH MukoyamaM KaiH ArimaH KarioK Effects of renal denervation on blood pressures in patients with hypertension: a systematic review and meta-analysis of randomized sham-controlled trials Hypertens Res 2022 45 210 220 Search in Google Scholar

[33] Qi XY, Cheng B, Li YL, Wang YF. Renal denervation, adjusted drugs, or combined therapy for resistant hypertension: A meta-regression. Medicine. 2016; Jul; 95: e3939. doi: 10.1097/MD.0000000000003939. QiXY ChengB LiYL WangYF Renal denervation, adjusted drugs, or combined therapy for resistant hypertension: A meta-regression Medicine 2016 Jul 95 e3939 10.1097/MD.0000000000003939 Open DOISearch in Google Scholar

[34] Silverwath J, Marti KE, Phan MT, Re Amin H, Roman YM, Pasupuleti V, Banach M, Barboza JJ, Hernandez AV. Renal denervation for uncontrolled and resistant hypertension: Systematic review and network meta-analysis of randomized trials. J Clin Med. 2021; 10: 782. doi: 10.3390/jcm10040782. SilverwathJ MartiKE PhanMT Re AminH RomanYM PasupuletiV BanachM BarbozaJJ HernandezAV Renal denervation for uncontrolled and resistant hypertension: Systematic review and network meta-analysis of randomized trials J Clin Med 2021 10 782 10.3390/jcm10040782 Open DOISearch in Google Scholar

[35] Stavropoulos K, Patoulias D, Imprialos K, Doumas M, Katsimardou A, Dimitriadis K, Tsioufis C, Papademetriou V. Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic reviewed meta-analysis of randomized, sham-controlled, catheter-based trials. J Clin Hypertens. (Greenwich). 2020; 22: 572–584. StavropoulosK PatouliasD ImprialosK DoumasM KatsimardouA DimitriadisK TsioufisC PapademetriouV Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic reviewed meta-analysis of randomized, sham-controlled, catheter-based trials J Clin Hypertens. (Greenwich) 2020 22 572 584 Search in Google Scholar

[36] Vogiatzakis N, Tsioufis C, Georgiopoulos G, Thomopoulos C, Dimitriadis K, Kasiakogias A, Konstantinidis D, Kalos T, Mahfoud F, Doumas M, Papademetriou V, Tousoulis D. Effect of renal sympathetic denervation on short-term blood pressure variability in resistant hypertension: a meta-analysis. J Hypertens. 2017; 35: 1750–1757. VogiatzakisN TsioufisC GeorgiopoulosG ThomopoulosC DimitriadisK KasiakogiasA KonstantinidisD KalosT MahfoudF DoumasM PapademetriouV TousoulisD Effect of renal sympathetic denervation on short-term blood pressure variability in resistant hypertension: a meta-analysis J Hypertens 2017 35 1750 1757 Search in Google Scholar

[37] Pappaccogli M, Covella M, Berra E, Fulcheri C, Di Monaco S, Perlo E, Burrello J, Monticone S, Rossato D, Rabbia F, et al. Effectiveness of renal denervation in resistant hypertension. A meta-analysis of 11 controlled studies. Cochrane Database Syst Rev. 2017; 2017(2): CD011499. doi: 10.1002/14651858.CD011499. PappaccogliM CovellaM BerraE FulcheriC Di MonacoS PerloE BurrelloJ MonticoneS RossatoD RabbiaF Effectiveness of renal denervation in resistant hypertension. A meta-analysis of 11 controlled studies Cochrane Database Syst Rev 2017 2017 2 CD011499 10.1002/14651858.CD011499 Open DOISearch in Google Scholar

[38] Chen C, Zhu XY, Li D, Zhou K, Lin Q. Clinical efficacy and safety of spironolactone in patients with resistant hypertension: A systematic review and meta-analysis. Medicine. 2020. 99: e21694. doi: 10.1097/MD.0000000000021694. PMID: 32846786. ChenC ZhuXY LiD ZhouK LinQ Clinical efficacy and safety of spironolactone in patients with resistant hypertension: A systematic review and meta-analysis Medicine 2020 99 e21694 10.1097/MD.0000000000021694 32846786 Open DOISearch in Google Scholar

[39] Schmieder RE, Mahfoud F, Mancia G, Azizi M, Böhm M, Dimitriadis K, Kario K, Kroon AAD, Lobo M, Ott C, et al. European Society of Hypertension position paper on renal denervation 2021. J Hypertens. 2021; 39: 1733–1741. SchmiederRE MahfoudF ManciaG AziziM BöhmM DimitriadisK KarioK KroonAAD LoboM OttC European Society of Hypertension position paper on renal denervation 2021 J Hypertens 2021 39 1733 1741 Search in Google Scholar

[40] Baik J, Song WH, Yim D, Lee S, Yang S, Lee HY, Choi EK, Jeong CW, Park SM. Laparoscopic renal denervation system for treating resistant hypertension: overcoming limitation of catheter-based approaches. Trans Biomed Eng. 2020; 67: 3425–3437. BaikJ SongWH YimD LeeS YangS LeeHY ChoiEK JeongCW ParkSM Laparoscopic renal denervation system for treating resistant hypertension: overcoming limitation of catheter-based approaches Trans Biomed Eng 2020 67 3425 3437 Search in Google Scholar

[41] Cai X, Yang Y, Shen Y, Wang W, Qian L, Cai J, Chi R, Fei Y, Yu S, Wei L, et al. Noninvasive stereotactic radiotherapy for renal denervation in a swine model. J Am Coll Cardiol. 2019; 74: 1697–1709. CaiX YangY ShenY WangW QianL CaiJ ChiR FeiY YuS WeiL Noninvasive stereotactic radiotherapy for renal denervation in a swine model J Am Coll Cardiol 2019 74 1697 1709 Search in Google Scholar

[42] Mahfoud F, Edelman E, Bhatt N. Stereotactic radiotherapy for renal denervation: to beam, or not to beam? J Am Cardiol. 2019; 74: 1710–1713. MahfoudF EdelmanE BhattN Stereotactic radiotherapy for renal denervation: to beam, or not to beam? J Am Cardiol 2019 74 1710 1713 Search in Google Scholar

[43] Lohmeier TE, Iliescu R, Terry M, Dwyer M, Lohmeier TE, Iliescu R, Terry M, Dwyer TM, et al. Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex. Am J Physiol Heart Circ Physiol. 2010; 299: H402–H409. LohmeierTE IliescuR TerryM DwyerM LohmeierTE IliescuR TerryM DwyerTM Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex Am J Physiol Heart Circ Physiol 2010 299 H402 H409 Search in Google Scholar

[44] Wallbach M, Halbach M, Reuter H, Passauer J, Lüders S, Böhning E, Zenker D, Müller GA, Wachter R, Koziolek MJ. Baroreflex activation therapy in patients with prior renal denervation. J Hypertens. 2016; 34: 1630–1638. WallbachM HalbachM ReuterH PassauerJ LüdersS BöhningE ZenkerD MüllerGA WachterR KoziolekMJ Baroreflex activation therapy in patients with prior renal denervation J Hypertens 2016 34 1630 1638 Search in Google Scholar

[45] Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG, Luft FC, Haller H, Menne S, Ceral S, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010; 56: 1254–1258. ScheffersIJ KroonAA SchmidliJ JordanJ TordoirJJ MohauptMG LuftFC HallerH MenneS CeralS Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study J Am Coll Cardiol 2010 56 1254 1258 Search in Google Scholar

[46] Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. Am Soc Hypertension. 2012; 6: 152–158. BakrisGL NadimMK HallerH LovettEG SchaferJE BisognanoJD Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial Am Soc Hypertension 2012 6 152 158 Search in Google Scholar

[47] Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, Cates AW, Lovett EG, Haller H. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012; 6: 270–276. HoppeUC BrandtMC WachterR BeigeJ RumpLC KroonAA CatesAW LovettEG HallerH Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial J Am Soc Hypertens 2012 6 270 276 Search in Google Scholar

[48] Spiering W, Williams V, Van der Heyden J, van Kleef M, Lo R, Versmissen J, Moelker A, Kroon A, Reuter H, Ansel G, et al. Endovascular baroreflex amplification for resistant hypertension: A safety and proof-of-principle clinical study. Lancet. 2017; 390: 2655–2661 SpieringW WilliamsV Van der HeydenJ van KleefM LoR VersmissenJ MoelkerA KroonA ReuterH AnselG Endovascular baroreflex amplification for resistant hypertension: A safety and proof-of-principle clinical study Lancet 2017 390 2655 2661 Search in Google Scholar

[49] Bates MC, Stone GW, Chen C-Y, Spiering W. Device profile on the MobiusHD EVBA system for the treatment of resistant hypertension: overview of its mechanism of action, safety and efficacy. Expert Rey Med Devices. 2020; 17: 649–665. BatesMC StoneGW ChenC-Y SpieringW Device profile on the MobiusHD EVBA system for the treatment of resistant hypertension: overview of its mechanism of action, safety and efficacy Expert Rey Med Devices 2020 17 649 665 Search in Google Scholar

[50] Groenland EH, Spiering W. Baroreflex amplification and carotid body modulation for the treatment of resistant hypertension. Curr Hypertens Rep. 2020; 22: 27. doi: 10.1007/s11906-020-1024-x GroenlandEH SpieringW Baroreflex amplification and carotid body modulation for the treatment of resistant hypertension Curr Hypertens Rep 2020 22 27 10.1007/s11906-020-1024-x Open DOISearch in Google Scholar

[51] Van Kleef MEAM, Devireddy CM, van der Heyden J, Bates MC, Bakris GL, Stone GW, Williams B, Spiering W. CALM-FIM Investigators. Treatment of resistant hypertension with endovascular baroreflex amplification: 3 years of results from CALM-FIM study: JACC Cardiovascular results from CALM-FJM study. JACC Cardiovascular Intrev. 2022; 15: 321–332. Van KleefMEAM DevireddyCM van der HeydenJ BatesMC BakrisGL StoneGW WilliamsB SpieringW CALM-FIM Investigators Treatment of resistant hypertension with endovascular baroreflex amplification: 3 years of results from CALM-FIM study: JACC Cardiovascular results from CALM-FJM study JACC Cardiovascular Intrev 2022 15 321 332 Search in Google Scholar

[52] Halbach M, Grothaus D, Hoffmann F, Madershahian N, Kuhr K, Reuter H. Baroreflex activation therapy reduces frequency and duration of hypertension-related hospitalizations in patients with resistant hypertension. Clin Auton Res. 2020; 30: 541–548. HalbachM GrothausD HoffmannF MadershahianN KuhrK ReuterH Baroreflex activation therapy reduces frequency and duration of hypertension-related hospitalizations in patients with resistant hypertension Clin Auton Res 2020 30 541 548 Search in Google Scholar

[53] Walbach M, Koziolek M. Baroreceptors in the carotid and hypertension-systematic review and meta-analysis of the effects of baroreflex activation therapy on blood pressure. Nephrol Dial Transplant. 2018; 33: 1485–1493. WalbachM KoziolekM Baroreceptors in the carotid and hypertension-systematic review and meta-analysis of the effects of baroreflex activation therapy on blood pressure Nephrol Dial Transplant 2018 33 1485 1493 Search in Google Scholar

[54] Chunbin W, Fu S, Jing H. Efficacy and safety of baroreflex activation therapy for treatment of resistant hypertension: a systematic review and meta-analysis. Clin Exp Hypertens. 2018; 40: 501–508. ChunbinW FuS JingH Efficacy and safety of baroreflex activation therapy for treatment of resistant hypertension: a systematic review and meta-analysis Clin Exp Hypertens 2018 40 501 508 Search in Google Scholar

[55] Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Müller-Ehmsen J, Schafer JE et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. JACC Heart Fail. 2015 Jun; 3: 487–496. AbrahamWT ZileMR WeaverFA ButterC DucharmeA HalbachM KlugD LovettEG Müller-EhmsenJ SchaferJE Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction JACC Heart Fail 2015 Jun 3 487 496 Search in Google Scholar

[56] Coats AJS, Abraham WT, Zile MR, Lindenfeld JA, Weaver FA, Fudim M, Bauersachs J, Duval S, Galle E, Zannad F. Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials. Eur J Heart Fail. 2022; 24: 1665–1673. CoatsAJS AbrahamWT ZileMR LindenfeldJA WeaverFA FudimM BauersachsJ DuvalS GalleE ZannadF Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials Eur J Heart Fail 2022 24 1665 1673 Search in Google Scholar

[57] Neuzil P, Merkely B, Erglis A, Marinskis G, de Groot JR, Schmidinger H, Rodriguez Venegas M, Voskuil M, Sturmberger T, et al. Pacemaker-mediated programmable hypertension control therapy. J Am Heart Assoc. 2017; 6: e006974. doi: 10.1161/JAHA.117.006974. NeuzilP MerkelyB ErglisA MarinskisG de GrootJR SchmidingerH Rodriguez VenegasM VoskuilM SturmbergerT Pacemaker-mediated programmable hypertension control therapy J Am Heart Assoc 2017 6 e006974 10.1161/JAHA.117.006974 Open DOISearch in Google Scholar

[58] Lauder L, Mahfoud F. Pacemaker-based cardiac neuromodulation therapy for the treatment of hypertension: the new kid on the block. J Am Heart Assoc. 2021; 10: e022622. doi: 10.1161/JAHA.121.022622 LauderL MahfoudF Pacemaker-based cardiac neuromodulation therapy for the treatment of hypertension: the new kid on the block J Am Heart Assoc 2021 10 e022622 10.1161/JAHA.121.022622 Open DOISearch in Google Scholar

[59] Bazoukis G, Korantzopoulos P, Tsioufis C. The impact of renal sympathetic denervation on cardiac electrophysiology and arrhythmias: A systematic review of the literature. Int J Cardiol. 2016; 220: 87–101. BazoukisG KorantzopoulosP TsioufisC The impact of renal sympathetic denervation on cardiac electrophysiology and arrhythmias: A systematic review of the literature Int J Cardiol 2016 220 87 101 Search in Google Scholar

[60] Lian Z, Yu SR, Song JX, Lee CY, Li SF, Cui YX, Su LN, Chen H. Efficacy and safety of catheter-based renal denervation for heart failure with reduced ejection fraction: a systematic review and meta-analysis. Clin Auton Res. 2020; 30: 521–530. LianZ YuSR SongJX LeeCY LiSF CuiYX SuLN ChenH Efficacy and safety of catheter-based renal denervation for heart failure with reduced ejection fraction: a systematic review and meta-analysis Clin Auton Res 2020 30 521 530 Search in Google Scholar

[61] Steinberg JS, Shabanov V, Ponomarev D, Losik D, Ivanickiy E, Kropotkin E, Polyakov K, Ptaszynski P, Keweloh B, Yao CJ, et al. Effect of renal denervation and catheter ablation vs catheter ablation alone on atrial fibrillation recurrence among patients with paroxysmal atrial fibrillation and hypertension: The ERADICATE-AF Randomized Clinical Trial. JAMA 2020; 21; 323: 248–255. doi: 10.1001/jama.2019.21187 SteinbergJS ShabanovV PonomarevD LosikD IvanickiyE KropotkinE PolyakovK PtaszynskiP KewelohB YaoCJ Effect of renal denervation and catheter ablation vs catheter ablation alone on atrial fibrillation recurrence among patients with paroxysmal atrial fibrillation and hypertension: The ERADICATE-AF Randomized Clinical Trial JAMA 2020 21 323 248 255 10.1001/jama.2019.21187 Open DOISearch in Google Scholar

[62] Kądziela J, Warchoł-Celińska E, Prejbisz A, Januszewicz A, Witkowski A, Tsioufis K. Renal denervation: can we press the “ON” button again in 2020? Postepy Kardiol Interwencyjnej. 2020 Sep; 16: 262–268. doi: 10.5114/aic.2020.99260. Epub 2020 Oct 2. PMID: 33597990 KądzielaJ Warchoł-CelińskaE PrejbiszA JanuszewiczA WitkowskiA TsioufisK Renal denervation: can we press the “ON” button again in 2020? Postepy Kardiol Interwencyjnej 2020 Sep 16 262 268 10.5114/aic.2020.99260 Epub 2020 Oct 2. 33597990 Open DOISearch in Google Scholar

[63] Nawar K, Mohammad A, Johns EJ, Abdulla MH. Renal denervation for arterial fibrillation: a comprehensive updated systematic review and meta-analysis. J Hum Hypertens. 2022; 36: 887–897. NawarK MohammadA JohnsEJ AbdullaMH Renal denervation for arterial fibrillation: a comprehensive updated systematic review and meta-analysis J Hum Hypertens 2022 36 887 897 Search in Google Scholar

[64] Warchol-Celinska E, Prejbisz A, Kadziela J, Florczak E, Januszewicz A, Michalowska I, Dobrowolski P, Kabat M, et al. Renal denervation in resistant hypertension and obstructive sleep apnea: randomized proof-of concept Phase II trial. Hypertension. 2018; 72: 381–390. Warchol-CelinskaE PrejbiszA KadzielaJ FlorczakE JanuszewiczA MichalowskaI DobrowolskiP KabatM Renal denervation in resistant hypertension and obstructive sleep apnea: randomized proof-of concept Phase II trial Hypertension 2018 72 381 390 Search in Google Scholar